What Labatec Pharma does

Labatec Pharma SA is a Swiss-based, privately held pharmaceutical company founded in Geneva in 1957 and currently headquartered in Meyrin. The firm develops, manufactures, and commercializes more than 65 specialty pharmaceutical products across hospital and retail segments, with therapeutic focus on anti-infectives, oncology, anaesthesia, anti-tuberculosis, women's health, osteoporosis, myorelaxants, CNS, ophthalmology, and cardiovascular indications. Its commercial footprint spans 13 countries — primarily Switzerland, Austria, and ten MENA markets — supplemented by a contract manufacturing organization (CMO) offering serving EU and global clients. The company is family-owned following its 2008 acquisition by Dr. Samih Darwazah, founder of Hikma Pharmaceuticals PLC, and operates with an agile, privately controlled structure that supports rapid product registration and market entry.

The company's product platform combines proprietary in-house brands (Mydocalm, Baclocalm, Penthrox, Papilocare, Eroxon, Multi-Gyn, Gynestral, EveryD3) with in-licensed assets such as TYMLOS (Radius Health) and MAXIGESIC IV (AFT Pharmaceuticals). Its manufacturing backbone is the 4,000m2 EU-GMP certified facility in Sintra, Portugal, opened in 2021, with annual capacity of up to 2 billion tablets for solid oral dosage forms. Notable technical differentiators include color-coded anti-infective packaging using Tall Man letters for high-risk medications, specialized cytostatic packaging designed to prevent cross-contamination, and unbreakable polypropylene pre-filled syringes compliant with ISMP/ISO 26825 standards for anaesthetic products. The company is also an approved supplier of Swissmedic-cleared anti-tuberculosis medicines to UN/WHO agencies, the Global Fund, and the Global Drug Facility.

Labatec's business model is a hybrid of proprietary product sales, in-licensing partnerships, and third-party contract manufacturing. It generates revenue through direct field sales in Switzerland and MENA, licensing royalties and commercialization fees for partner products, and CMO services billed via its [email protected] channel. Distribution combines direct enterprise sales teams with extensive local distribution agency networks for rapid product registration in emerging markets. GTM motions span enterprise field sales for hospital and retail accounts, channel partners for MENA/EU expansion, and sales-led outreach for CMO contracts. Strategic growth has been supported by sequential in-licensing, geographic expansion (most recently a 2023 Dubai commercial office), and operational scale-up in Portugal.

Name

Labatec Pharma

Legal name

Labatec Pharma SA

Website

https://labatecpharma.com

Company type

Private

Founded year

1957

Operating status

Operating

Headcount range

101–250 employees

Short description

Labatec Pharma is a Swiss-based, privately held pharmaceutical company founded in 1957 that develops, manufactures, and commercializes over 65 specialty products across hospital and retail segments in Switzerland, MENA, and select EU markets, with additional EU-GMP contract manufacturing services.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Pharmaceutical manufacturing
• Hospital injectables
• Specialty pharmaceuticals
• Contract manufacturing services
• Generic medicines

Headquarters

HQ city

Genève

HQ country

Switzerland

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of proprietary pharmaceutical products including injectables, orals, and OTC products across hospital and retail segments in Switzerland and MENA markets.
2. Licensing Partnerships: In-licensing innovative medicines (e.g., MAXIGESIC IV®, TYMLOS®) for commercialization in Switzerland and MENA regions. Labatec handles sales, marketing, medical affairs, pricing, and reimbursement while partners supply the drug.
3. Contract Manufacturing Services: EU-GMP certified manufacturing and packaging services for solid oral dosage form products. Offers end-to-end project approach with flexible and scalable solutions for third-party pharmaceutical companies.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Labatec Pharma is a Swiss-based pharmaceutical company that develops, manufactures, and commercializes a portfolio of over 65 pharmaceutical products across hospital (injectables and orals for anti-infectives, anaesthesia, ICU, oncology, and anti-tuberculosis) and retail sectors (osteoporosis, muscle relaxants, women's health, ophthalmology, OTC). The company also offers EU-GMP certified contract manufacturing services for solid oral dosage forms at its Portugal facility.

Product overview

Labatec Pharma is a Swiss-based privately owned pharmaceutical company with over 50 years of experience delivering high-quality pharmaceutical products. The company operates across two main segments: hospital (injectables and orals for anti-infectives, anaesthesia, ICU, oncology, antiemetics, and anti-tuberculosis) and retail (specialty prescription products in musculoskeletal/osteoporosis, women's health including contraceptives and vaginal health, CNS, and ophthalmology, plus OTC products). Key hospital portfolios include 30+ anti-infectives, 20+ oncology products, anaesthesia products in pre-filled syringes, and anti-tuberculosis medicines. Retail portfolio spans myorelaxants (Baclocalm, Metoflex, Mydocalm), osteoporosis treatments (Tymlos, Binosto, Zoledronat), women's health products (contraceptives, menopause, fertility, vaginal health), CNS products (Redormin, Remotiv 500), and OTC supplements (Gynestral, Multi-Gyn, EveryD3, Winforce L-Carnitine). Licensed products include Maxigesic IV (pain management) from AFT Pharmaceuticals and TYMLOS (osteoporosis) from Radius Health. The company also offers EU-based contract manufacturing services for solid oral dosage forms.

Differentiator

Problem solved

Functional benefit

Brands

• Papilocare: First specific treatment for the prevention and treatment of low grade cervical lesions caused by papillomavirus
• Gynestral
• Multi-Gyn
• EveryD3
• Penthrox
• Ty mlos
• Mydocalm
• Maxigesic IV

Products and services

• Anti-infectives Portfolio Portfolio of 30+ European-manufactured injectable and oral anti-infective medicines including antivirals (Aciclovir), antifungals (Anidulafungin, Caspofungin, Fluconazol), and antibiotics (Cefazolin, Ceftriaxon, Cefuroxim, Clarithromycin, Co-Amoxicillin, Daptomycin, Imipenem-Cilastatin, Meropenem, Piperacillin-Tazobactam, Rifamipicin IV, Teicoplanin, Vancomycin) for hospital use.
• Oncology Portfolio Portfolio of over 20 oncology product references including injectable and oral medicines such as Cabazitaxel, CARBOplatin, Fluorouracil, Hydroxycarbamid, Irinotecan, Letrozol, Octreotid, Ondansetron, Paclitaxel, Palonosetron, Pemetrexed, and Zoledronic acid, manufactured to European quality standards with specialized cytostatic packaging.
• Women's Health Portfolio Comprehensive women's health portfolio with over 20 years of experience, including contraceptives (Bijuva, Desogyn, Seasonique, Zoely, Ganirelix, Ovaleap), menopause treatments (Femoston, Duphaston), vaginal health products (Multi-Gyn, Softigyn, Intrarosa), fertility treatments, and urinary incontinence products.
• Myorelaxants Muscle relaxant products with over 50 years of clinical use, including Baclocalm, Metoflex, and Mydocalm, well-established in Switzerland and Emerging Markets.
• Osteoporosis Portfolio Products for osteoporosis treatment including Binosto, Lundeos, Tymlos (abaloparatide), and Zoledronat for postmenopausal women at high risk for fracture.
• Anti-tuberculosis Portfolio Anti-tuberculosis medicines including Isoniaz-TB, Myambutol, Pyrazinamide, and Rifampicin. Products are Swissmedic-approved and supplied to UN/WHO agencies, Global Fund, and Global Drug Facility.
• Anaesthesia Portfolio High-value anaesthesia products including aTRAcurium, Dexmedetomidin, Flumazenil, Ketamin, and Rocuronium, available in pre-filled syringe presentations with safety features.
• Penthrox® Emergency medicine product for inhalation analgesia, used for emergency and procedural sedation applications.
• Cardio-Vascular Products Cardiovascular medicines including Amiodaron and Milrinon for hospital use.
• Central Nervous System Products CNS products including Redormin and Remotiv 500 for neurological and psychiatric indications.
• Ophthalmology Products Ophthalmology products including Moxitec and ZetaMac for eye conditions.
• Winforce L-Carnitine Sport nutrition supplement containing L-Carnitine for athletic performance support.
• Esolab PPI (Proton Pump Inhibitor) product for acid-related disorders.
• Eroxon Product for erectile dysfunction treatment, available OTC.
• Papilocare® First specific treatment for the prevention and treatment of low grade cervical lesions caused by papillomavirus (HPV).
• Maxigesic IV® Innovative intravenous pain relief medicine for treatment of mild to moderate pain for post-operative use in hospitals when patients cannot take medicine orally, licensed from AFT Pharmaceuticals.
• TYMLOS® (abaloparatide) Subcutaneous injection for treatment of postmenopausal women with osteoporosis at high risk for fracture, licensed from Radius Health for exclusive commercialization in Switzerland and MENA region.
• Contract Manufacturing Services Full contract manufacturing services for solid oral dosage form products, providing end-to-end project approach with flexible and scalable manufacturing and packaging solutions at an EU-GMP certified 4,000m2 facility in Portugal.

Quantifiable outcome

• Business expanded fivefold within eight years following 2008 acquisition
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• AFT PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 27 March 2023Exclusive licensing agreement for commercialization of MAXIGESIC IV® in Switzerland. Labatec handles sales, marketing, medical affairs, pricing, and reimbursement while AFT supplies the drug. Both companies aim for registration and launch within 12-18 months in Switzerland. MAXIGESIC IV® treats mild to moderate post-operative pain when patients cannot take oral medication.
• Radius Health Inc.coreOEM/ Whitelabel/ Licensing Partner · 9 June 2022Exclusive licensing agreement for commercialization of TYMLOS® (abaloparatide) in Switzerland and MENA region including Bahrain, Iraq, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, UAE, Algeria, and Morocco. Labatec handles registration, commercialization, and distribution with all commercial activities including sales, marketing, medical affairs, pricing, and reimbursement. TYMLOS® is a subcutaneous injection for osteoporosis treatment in postmenopausal women at high risk for fracture.
• Stop TB PartnershipcoreStrategic or Co-development PartnerCollaboration with Stop TB Partnership to supply high-quality Swissmedic-approved anti-tuberculosis medicines. Supports global efforts to combat tuberculosis which affects over 10 million people and causes 1.7 million deaths annually.
• Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM)coreStrategic or Co-development PartnerListed as approved supplier to GFATM for anti-tuberculosis medicines. Collaboration to provide affordable, high-quality TB treatments to patients in need.
• Global Drug Facility (GDF)coreChannel Partner/ Reseller/ DistributorListed as approved supplier to Global Drug Facility for anti-tuberculosis medicines under WHO/UN programs.
• EsteveminorChannel Partner/ Reseller/ DistributorPartner company logo displayed on partnering page - nature of partnership not detailed.
• Reig JofreminorChannel Partner/ Reseller/ DistributorPartner company logo displayed on partnering page - nature of partnership not detailed.
• EirGen PharmaminorChannel Partner/ Reseller/ DistributorPartner company logo displayed on partnering page - nature of partnership not detailed.
• NTCminorChannel Partner/ Reseller/ DistributorPartner company logo displayed on partnering page - nature of partnership not detailed.
• TheramexminorChannel Partner/ Reseller/ DistributorPartner company logo displayed on partnering page - nature of partnership not detailed.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Stada Arzneimittel: German-headquartered European generics and specialty pharma player with significant hospital injectables, biosimilars and consumer health franchises. Comparable in generics manufacturing plus in-licensing strategy, but at materially larger scale than Labatec.
• Gedeon Richter: Hungary-based specialty and generics pharmaceutical group with strong women's health and CNS portfolios, plus a CMO business serving global pharma. Comparable in the women's health specialty overlap (contraceptives, menopause) and emerging markets footprint.
• Almirall: Spain-based dermatology-focused specialty pharma with European and international presence. Comparable as a mid-sized European specialty pharma with in-licensing and portfolio diversification strategy, though more concentrated in dermatology.
• Hikma Pharmaceuticals: Jordan/UK-based specialty and injectable pharmaceutical company founded by Labatec's owner Dr. Samih Darwazah. Directly comparable in MENA-focused injectables/hospital portfolio, generics pipeline, and European manufacturing footprint, but at much larger scale and public.

Direct peers

• AFT Pharmaceuticals: New Zealand/Australia-based specialty pharma that licenses products like MAXIGESIC IV to Labatec for Swiss commercialization. Comparable as a small-cap specialty pharma using licensing partnerships to access European and emerging markets rather than building direct infrastructure.
• Reig Jofre: Barcelona-based specialty pharmaceutical company with hospital injectables, biosimilars and specialty pharma divisions, listed as a Labatec channel partner. Comparable in mid-sized European specialty pharma profile with hospital/retail portfolio and emerging market expansion.
• Acino Pharmaceuticals: Swiss-headquartered specialty pharmaceutical company focused on generics and in-licensed brands across emerging markets. Closely comparable business model to Labatec — Swiss base, hospital + specialty retail portfolio, MENA/EMEA distribution — and explicitly referenced through Labatec board director Jostein Davidsen's prior CEO role.
• EirGen Pharma: Irish specialty pharma focused on women's health and oncology generics, listed as a Labatec channel partner. Comparable in specialty generics, women's health focus and partnership-driven international expansion model.
• Esteve: Spanish family-owned specialty pharmaceutical company with a hospital, generics and licensing model, also listed as a Labatec channel partner. Closely comparable in scale, ownership structure and specialty pharma/injectables focus.

Regional players

• Polpharma: Poland's largest pharmaceutical manufacturer with generics, OTC and API operations across Central/Eastern Europe and CIS. Comparable generics + CMO business model, though primarily focused on Eastern European rather than MENA markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/labatec-pharma-sa
• Facebookfacebook.com/Labatec-Pharma-952933855097320

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Labatec Pharma